Not only does 5-aza-2-deoxycytidine (5-aza-CdR) induce the reexpression of silenced genes through the demethylation of CpG islands, but it increases the expression of unmethylated genes. However, the mechanism by which 5-aza-CdR activates the expression of genes is not completely understood. Here, we report that the pRb pocket proteins pRb, p107, and p130 were degraded in various cancer cell lines in response to 5-aza-CdR treatment, and this effect was dependent on the proteasome pathway. Mouse double minute 2 (MDM2) played a critical role in this 5-aza-CdR-induced degradation of pRb. Furthermore, PP2A phosphatase-induced MDM2 dephosphorylation at S260 was found to be essential for MDM2 binding to pRb in the presence of 5-aza-CdR. pRb degradation resulted in the significant reexpression of several genes, including methylated CDKN2A, RASFF1A, and unmethylated CDKN2D. Finally, knockdown of pRb pocket proteins by either RNAi or 5-aza-CdR treatment induced a significant decrease in the recruitment of SUV39H1 and an increase in the enrichment of KDM3B and KDM4A to histones around the promoter of RASFF1A and thus reduced H3K9 di-and trimethylation, by which RASFF1A expression is activated. Our data reveal a novel mechanism by which 5-aza-CdR induces the expression of both methylated and unmethylated genes by degrading pRb pocket
5-Aza-2Ј-deoxycytidine (5-aza-CdR) is an analog of cytosine that is converted into a nucleotide triphosphate in vivo. Thus, it is able to incorporate into the DNA and influence DNA structure and stability (1-3). 5-Aza-CdR is also an effective demethylating agent, and it is used extensively in the study of epigenetic regulation (3) . Two models have been proposed to explain the mechanism by which 5-aza-CdR reactivates silenced genes by demethylating CpG islands in the promoters. First, after being incorporated into DNA, 5-aza-CdR forms an irreversible and covalent bond with DNA methyltransferase 1 (DNMT1), which is mainly responsible for the maintenance of DNA methylation. This therefore leads to demethylation when DNA replicates (1, 2, 4) . Second, 5-aza-CdR is reported to induce degradation of DNMT1 through a ubiquitin-proteasome-dependent pathway that results in gene reexpression (5) .
On the other hand, 5-aza-CdR is also able to induce DNA methylation-independent gene reactivation. For example, 5-aza-CdR induces the expression of unmethylated Apaf-1 and CDKN2D (encoding p19), and thus elicits apoptotic cell death in human cancer cells (6, 7) . These DNA demethylation-independent mechanisms of 5-aza-CdR-regulated gene expression may be related to DNA damage caused by 5-aza-CdR. 5-Aza-CdR was shown to activate p53 expression in human colon cancer and human lung cancer cell lines (8, 9) . This finding was confirmed to be secondary to 5-aza-CdRinduced DNA damage (10 -12) . Furthermore, it has been reported that 5-aza-CdR-induced gene reactivation is related to changes in histone methylation. 5-Aza-CdR, for example, induces degradation of G9A, a histone methyltransferase, resulting in a global decrease in H3K9 dimethylation at the promoters of specific genes, but the process does not induce changes in DNA methylation (13) . Therefore, the mechanism of 5-aza-CdR-induced gene reactivation is very complex and may depend on cell type and the gene being tested.
The pRb pocket proteins, including pRb, p107, and p130, play a critical role in controlling the transition from G 1 to S phase during cell cycle progression (14) . It has also been reported that pRb pocket proteins form a repressive complex with DNMT1, histone deacetylase 1 (HDAC1), and E2F1 (15) , which implies that the functions of pRb may be associated with DNA methylation and/or histone modifications. As reported previ-ously, pRb cooperates with HDAC1 to repress E2F-regulated cyclin E (16) . In addition, pRb also interacts with histone modifying enzymes on the targeted promoters to inhibit gene expression. For example, Rb directly binds to the histone methyltransferase SUV39H and to effector protein HP1 (17) . Moreover, it mediates histone 3 lysine 9 (H3K9) methylation, which creates a recognition and binding site for HP1, resulting in a condensed chromatin structure and gene silencing (17) .
This study attempted to determine whether 5-azaCdR activates gene expression by influencing either the function or the stability of pRb. We found that the pRb pocket proteins were degraded via a mouse double minute 2 (MDM2)-modulated proteasome-dependent pathway in human cancer cell lines on treatment with 5-aza-CdR. The phosphatase PP2A was activated in response to 5-aza-CdR treatment, by which MDM2 was dephosphorylated at S260. Hypophosphorylated MDM2 was required for pRb degradation on treatment with 5-aza-CdR. Consequently, histone modifications were significantly changed on pRb degradation, and silenced genes were reactivated.
MATERIALS AND METHODS

Cell lines and drug treatment
The human lung cancer cell lines (A549, H1299, and H719), human colon cancer cell lines [HCT116 (p53
) and HCT116 (p53 ϩ/ϩ )], and human osteosarcoma cell line (U2OS) used in this study were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum and 100 g/ml streptomycin-penicillin. Cells were treated with 5-aza-CdR (Sigma-Aldrich, St. Louis, Mo, USA) for up to 96 h at various concentrations or 5-aza-CdR (1 M) for different durations. Fresh medium containing 5-aza-CdR was replaced every 24 h.
Plasmid construction and transfection
A Flag-MDM2 plasmid, which expresses full length wild-type MDM2, was generated by amplifying the cDNA from human cells and ligating the PCR product into the p3XFLAG-CMV-10 expression vector. Specific site mutations were generated in the Flag-MDM2 plasmid using the QuikChange site-directed mutagenesis kit (Stratagene, Offenbach, Germany) in accordance with the manufacturer's instructions. The pSG5-Rb plasmid encoding full length pRb was a gift of Hongquan Zhang. pSG5-Rb and Flag-MDM2 wild-type or mutant plasmids were transfected into U2OS cells for 48 h using Effectene transfection reagent (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions.
Western blot analysis and coimmunoprecipitation (CoIP)
Cells were lysed with buffer (1% Nonidet P-40, 150 mM NaCl, 50 mM Tris-HCl, 0.05% SDS, and proteasome inhibitors) on ice for 20 min. The lysed extracts were centrifuged at 14,000 rpm for 15 min, and the supernatant was subjected to immunoprecipitation with the indicated antibodies. The protein complex was then pulled down by protein G-agarose beads (GE Healthcare, Piscataway, NJ, USA). The antibodies used were anti-phosphoserine (05-1000; Upstate, Lake Placid, NY, USA), anti-pRb (sc-102 and sc-65608; Santa Cruz Biotechnology, Burlingame, CA, USA), anti-MDM2 (RB-9218-P1; NeoMarkers, Fremont, CA, USA), anti-PP2A (A300 -731A; Bethyl Laboratories, Inc., Montgomery, TX, USA), and anti-␣-tubulin (sc-23948; Santa Cruz Biotechnology). Protein bands were analyzed and compared using the Quantity One 1-D software (Bio-Rad Laboratories, Hercules, CA, USA).
RNA interference
Sequences of RNA interference (RNAi) oligonucleotides for controls (nonsilencing), Rb, p107, p130, MDM2 and PP2A were as follows: nonsilencing small interfering RNA (siRNA), UUCUCCGAACGUGUCACGU; Rb siRNA, GGACAUGU-GAACUAUAUA and GAACGAUUAUCCAUUCAAA; p107 siRNA, GCGAUUAUGUGCCCAAAUA and GAAGUUAUAU-UCCCAAAUA; p130 siRNA, GGAGAUGCUUUACUAUAAA; MDM2 siRNA, CGCCACAAAUCUGAUAGUAUU; and PP2A siRNA, CCGGAUACAAACUACUUAUUU. These RNAi oligonucleotides were transfected into U2OS cells using the Lipofectamine 2000 transfection kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. To determine whether 5-aza-CdR-induced pRb degradation is MDM2 dependent, MDM2 RNAi was performed before treatment with 5-aza-CdR.
Methylation-specific PCR
Briefly, genomic DNA (1 g) in a volume of 50 l was denatured with NaOH (final concentration, 0.275 M) for 20 min at 42°C. The denatured DNA was then treated with 10 l of 10 mM hydroquinone and 520 l of 3 M sodium bisulfite at 50°C overnight. The primers for methylationspecific PCR (MS-PCR) of the CDKN2A, RASSF1A, and CDKN2D promoters were designed as follows: methylated CDKN2A, forward primer 5Ј-TTATTAGAGGGTGGGGCG-GATCGC-3Ј and reverse primer 5Ј-GACCCCGAACCGC-GACCGTAA-3Ј; unmethylated CDKN2A, forward primer 5Ј-TTATTAGAGGGTGGGGTGGATTGT-3Ј and reverse primer 5Ј-CAACCCCAAACCACAACCATAA-3Ј; methylated RASSF1A, forward primer 5Ј-TTTTAGAAATACGGGTATTTTCGC-3Ј and reverse primer 5Ј-GTACTTCGCTAACTTTAAACGCT-3Ј; unmethylated RASSF1A, forward primer 5Ј-TTAGAAATATGG-GTATTTTTGTGT-3Ј and reverse primer 5Ј-CCATACTTCA-CTAACTTTAAACACT-3Ј; methylated CDKN2D, forward primer 5Ј-GCGTGCGTAATGGGTTATAGAATC-3Ј and reverse primer AACCGACGAAACCACTCGAC; unmethylated CDKN2D, forward primer 5Ј-TGTGTGTAATGGGTTATA-GAATT-3Ј and reverse primer 5Ј-AAATCAACCAACAAAAC-CACTCAAC-3Ј.
Bisulfite sequencing
DNA was treated with sodium bisulfite and purified for PCR as described previously (18, 19) . The primers for sequencing the CDKN2A, RASSF1A, and CDKN2D promoters were as follows: CDKN2A, forward primer 5Ј-GGTAGGTGGGGAGGAGTTTAG-3Ј and reverse primer 5Ј-CCAACCCCTCCTCTTTCTTC-3Ј; RASSF1A, forward primer 5Ј-GTAGGTTAAGTGTGTTGTTTTAGTA-3Ј and reverse primer 5Ј-ACCAAAAACCAACTACCRTATAAAATT-3Ј; CDKN2D, forward primer AGGAGGGAGGGTGAGTTAG and reverse primer AACCTCCTCCAACAACATATC. The PCR products were gel extracted (Qiagen) and ligated into the pGEM-T easy vector using the TA cloning system (Promega, Madison, WI, USA). At least 10 separate clones were chosen for sequence analysis.
RT-PCR and real-time PCR
Total RNA was isolated using Trizol reagent (Invitrogen). cDNA was synthesized from 2 g of RNA with oligo(dT) 18 primers using the SuperScript kit (Invitrogen). The primer sequences used for real-time PCR were as follows: p16, forward primer 5Ј-CATAGATGCCGCGGAAGGT-3Ј and reverse primer 5Ј-CCCGAGGTTTCTCAGAGCCT-3Ј; RASSF1A, forward primer 5Ј-TTGGAGACCCTGCAAACAGAACAG-3Ј and reverse primer 5Ј-GTACAGCATGTGCCTTAATGCTTC-3Ј; p19, forward primer 5Ј-CAACCGCTTCGGCAAGAC-3Ј and reverse primer 5Ј-AAGCAAGGTGCCAGCCC-3Ј.
ChIP assay and q-ChIP PCR
Briefly, ϳ2 ϫ 10 7 cells were fixed with 1% formaldehyde at 37°C for 10 min, and then they were lysed on ice for 15 min. These lysed extracts were subjected to shearing by sonication. After centrifugation at 14,000 rpm for 15 min, the soluble chromatin was subjected to immunoprecipitation with antibodies against various modified histones and other proteins as indicated (19) . Antibodies used were anti-dimethyl-H3K9 (17-648; Upstate), anti-trimethyl-H3K9 (07-523; Upstate), anti-trimethyl-H3K27 (07-449; Upstate), anti-G9A (ab40542; Abcam, Cambridge, UK), anti-SUV39H1 (05-615; Upstate), anti-EZH2 (ab3748; Abcam), anti-KDM3A (ab91252; Abcam), anti-KDM3B (ab70797; Abcam), and KDM4A (ab24545; Abcam). The primer sequences for all ChIPs and quantitative ChIP (q-ChIP) PCRs were as follows: RASSF1A, forward primer 5Ј-GGACCCTCTTCCTCTAGCACAGT-3Ј and reverse primer 5Ј-GCACCACGCGGAGATACC-3Ј; CDKN2D, forward primer 5Ј-TC-CCTTTCTTCACGGTGCTT-3Ј and reverse primer 5Ј-GCGTC-GCTCCTGATTGGTC-3Ј.
Statistical analysis
All experiments were repeated Ն3 times. Data of quantitative real-time PCR and band intensity were analyzed using Student's t test to check differences between groups. A value of P Ͻ 0.05 was considered statistically significant.
RESULTS
5-Aza-CdR induces the degradation of pRb pocket proteins
To investigate whether 5-aza-CdR influences the phosphorylation status or stability of the pRb pocket proteins, human lung cancer cell line A549 was exposed to 5-aza-CdR at 1 M for 48 or 96 h, and protein was extracted for Western blotting. Figure 1A shows that the level of all pRb pocket proteins, including pRb, p107, and p130, significantly decreased in response to 5-azaCdR treatment in a time-dependent manner. For example, the protein level of pRb, p107, and p130 decreased 3-, 15-, and 5-fold, respectively, in A549 cells treated with 1 M for 96 h (EC 50 0.5 M). We also observed that pRb almost disappeared when cells were treated with 5-aza-CdR at 5 M for 96 h (Fig. 1B) . In addition, we noticed that both hyperphosphorylated and hypophosphorylated pRb decreased in response to 5-aza-CdR treatment, indicating that 5-aza-CdR-induced changes in pRb level did not result from phosphorylation changes. This 5-aza-CdR-induced decrease in pRb pocket proteins did not result from transcriptional inhibition, because 5-aza-CdR did not reduce the mRNA level of any of the three pocket proteins at either the highest dose or the longest treatment time ( Fig. 1C-F ). These data suggest that pRb pocket proteins may be degraded in response to 5-aza-CdR treatment.
To determine whether 5-aza-CdR-induced pRb degradation is generalizable to other cell lines, several human cancer cell lines, including a human osteosarcoma cell line (U2OS), 3 human lung cancer cell lines (H23, H1299, and H719), and 2 human colon cancer cell lines [HCT116 (p53
) and HCT116 (p53
)], were exposed to 5-aza-CdR at 1 M for 48 or 96 h, and protein was then extracted for Western blotting. Figure 2 shows that 5-aza-CdR was able to induce a significant decrease in pRb protein in all cell lines tested, indicating that 5-aza-CdR-induced degradation of pRb is a general phenomenon. Notably, pRb expression was decreased in both HCT116 (p53 ϩ/ϩ ) and HCT116 (p53 Ϫ/Ϫ ) cells in response to 5-aza-CdR, implying that p53 may be not involved in the process. 
MDM2 is required for 5-aza-CdR-induced degradation of pRb
To determine which protein degradation pathway is involved in 5-aza-CdR-induced degradation of pRb pocket proteins, a specific proteasome inhibitor (MG132) and a specific lysosome protease inhibitor (chloroquine; CHQ) were used. Figure 3A shows that the 5-aza-CdR-induced decrease in pRb was blocked by MG132, but not by the CHQ, indicating that this decrease in pRb level is due to enhanced proteasome-dependent degradation. We also used cycloheximide (CHX), an inhibitor of protein synthesis, to inhibit protein synthesis, and then measured the half-life of pRb in the presence of 5-aza-CdR. As shown in Fig. 3B , the half-life of pRb decreased from Ͼ10 h in untreated cells to ϳ8 h in the 5-aza-CdR treated cells, indicating a destabilization of pRb in the presence of 5-aza-CdR (Fig. 3B) . Because hypophosphorylated pRb is also reported to be associated with core filaments of nuclear matrix during early G 1 phase (20, 21), we isolated the nuclear matrix and investigated the pRb level located in the nuclear matrix. Both soluble pRb (part 2) and pRb level located in the nuclear matrix (part 5) were also decreased markedly in A549 cells in response to 5-aza-CdR treatment (Supplemental Fig. S1 ). We next asked whether ubiquitin is required for the degradation of pRb in response to 5-aza-CdR treatment using a CoIP assay. A549 cells were treated with 5-aza-CdR at 1 M for 48 or 96 h, and protein was immunoprecipitated with antipRb and blotted with antiubiquitin. Compared to p53 polyubiquitination (as a positive control), we did not observe polyubiq- (Fig. 3C) .
Because pRb has been reported to undergo MDM2-modulated degradation through both ubiquitin-dependent and ubiquitin-independent proteasomal pathways (22, 23), we performed a CoIP assay to determine whether 5-aza-CdR treatment induces an interaction between pRb and MDM2. As shown in Fig. 3D , there was a 5.3-fold increase in the interaction between pRb and MDM2 in response to 5-aza-CdR treatment compared to untreated sample. This data may reflect that pRb degradation is the consequence of the increased interaction between pRb and MDM2. To further confirm MDM2 as an E3 ligase for pRb degradation induced by 5-aza-CdR, an RNAi against MDM2 was employed in A549 cells, and pRb level was monitored. Figure 3E shows that 5-aza-CdR-induced degradation of pRb was completely blocked when MDM2 was knocked down.
Finally, we used a double-knockout mouse embryo fibroblast (MEF) cell line (p53 Ϫ/Ϫ and MDM2
Ϫ/Ϫ
MEFs) to further confirm the role of MDM2 in modulating 5-aza-CdR-induced pRb degradation. As shown in Fig. 3F , pRb was not degraded by 5-aza-CdR, suggesting that MDM2 is essential for 5-aza-CdR-induced pRb degradation.
Dephosphorylation of MDM2 catalyzed by PP2A phosphatase is required for MDM2 to bind to pRb
Because the activity of MDM2 is regulated by posttranslational modifications (24), we asked whether 5-aza-CdR treatment induces changes in the phosphorylation, acetylation, or methylation of MDM2. A549 cells were treated with 5-aza-CdR and protein was then extracted for immunoprecipitation with anti-MDM2 and blotted with anti-phosphoserine, anti-acetyllysine, or anti-methyllysine. We did not observe any changes in MDM2 acetylation or methylation in the 5-aza-CdR treated cells (data not shown). Interestingly, we observed a significant decrease in the total serine phosphorylation level of MDM2 in response to 5-aza-CdR (Fig. 4A) , indicating that the dephosphorylation of MDM2 may be required for MDM2 to bind to pRb. To determine whether the 5-aza-CdR-induced hypophosphorylation of MDM2 is critical for MDM2 binding to pRb, we generated several flag-tagged MDM2 constructs with mutations in the pRb binding region (between aa 254 -264; ref. 25) . In 3 separate constructs, serines S256, S260, and S262 in this region were individually replaced with alanines to mimic the dephosphorylated state. After transfection of A549 cells with Flag-Tagged mutated MDM2, extracted protein was coimmunoprecipitated with anti-pRb and blotted with anti-flag. As shown in Fig. 4B , MDM2 mutated at S260 showed increased binding to pRb, whereas MDM2 mutated at S256 or S262 did not show any significant increase in binding to pRb, indicating that MDM2 dephosphorylation at S260 is important for MDM2 to bind to pRb.
Next, we sought to identify the enzymes that dephosphorylate MDM2 at S260 in response to 5-aza-CdR treatment. Figure 4C , D shows that the mRNA and protein levels of PP2A were unchanged in A549 cells in response to 5-aza-CdR treatment, which raised the possibility that 5-aza-CdR may promote MDM2 dephos- phorylation by promoting interaction between MDM2 and PP2A. To evaluate this hypothesis, a Co-IP assay was performed to assess the interaction between MDM2 and PP2A. Figure 4E shows that PP2A was able to bind to MDM2 in untreated cells, and the interaction between MDM2 and PP2A was significantly enhanced after 5-aza-CdR treatment. To further determine the effect of PP2A in 5-aza-CdR-induced MDM2 dephosphorylation, a PP2A RNAi was introduced into A549 cells, and they were then exposed to 5-aza-CdR (1 M for 96 h). As shown in Fig. 4F , knockdown of PP2A significantly attenuated the decrease in the phosphoserine level of MDM2 in A549 cells in response to 5-aza-CdR treatment. Also, knockdown of PP2A reduced the pRb degradation caused by 5-aza-CdR (Fig.  4G ). These data suggest that PP2A is a critical enzyme for both MDM2 dephosphorylation and the degradation of pRb in response to 5-aza-CdR treatment. Furthermore, to identify the DNA damage sensor responsible for pRb degradation, RNAi against ATM or ATR was introduced into A549 cells, and then exposed to 5-aza-CdR treatment (1 M for 96 h). Knockdown of ATM, but not ATR, significantly reduced the pRb degradation caused by 5-aza-CdR (Supplemental Fig.  S2 ), indicating that ATM might be a DNA damage sensor to modulate the process of the 5-aza-CdR-induced pRb degradation.
Degradation of the pRb pocket proteins activates gene expression without changes in DNA methylation
Because 5-za-CdR is a DNA demethylating agent, here we paid more attention to investigating whether 5-aza-CdR-activated gene expression is associated with its demethylation function or induction of pRb degradation. First, methylation-specific PCR (MS-PCR) was performed to detect the methylation status of several genes in U2OS cells. As shown in Fig. 5B , CDKN2A and RASFF1A were hypermethylated in U2OS cells, and CDKN2D was not methylated. We next generated a stable triple-knockdown (TKD) cell line against pRb, p107, and p130 (Fig. 5C ) to assess the expression pattern of the tested genes after 5-aza-CdR treatment. In response to 5-aza-CdR treatment, hypermethylated CDKN2A became unmethylated, whereas no methylation changes were found in the Cpg island of RASSF1A or CDKN2D, as demonstrated by bisulfite sequencing (Fig. 5D, E) . We also detected the methylation changes in the CpG island shore in RASSF1A promoter (Ϫ1050 to Ϫ198) and found that the CpG island shore and the Sp1 binding site within this region are not hypermethylated in U2OS cells (Fig. 5E) . In response to 5-aza-CdR treatment or TKD of pRb pocket proteins, no significant changes in methylation of the CpG island shore and the Sp1 binding sites were observed (Fig. 5E) . With Western blotting, we observed that pRb was significantly decreased in both TKD-and 5-aza-CdR-treated cells, and the 5-aza-CdR-induced decrease in pRb was rescued when cells were transfected with PSG5-Rb plasmid (Fig. 5F ). As shown in Fig. 5G , TKD of Rb family proteins induced 70.2-, 3.2-, or 1.5-fold increase in the mRNA level of CDKN2A, RASSF1A, or CDKN2D, respectively. Consistent with the data of TKD, 5-aza-CdR also induced 118.6-, 5.4-, or 1.9-fold increase in the mRNA level of CDKN2A, RASSF1A, or CDKN2D, respectively. The expression of these genes in TKD-treated U2OS cells was less than that in 5-aza-CdR-treated cells, which implies that 5-aza-CdR, as a compound, may activate gene expression by multiple mechanisms.
However, the expression of these genes was significantly attenuated in 5-aza-CdR-treated cells when pRb was overexpressed exogenously via transfected pSG5-Rb (Fig. 5G) . These data suggest that the gene activation induced by pRb degradation, at least that of RASSF1A and CDKN2D, is not related to DNA demethylation.
Degradation of pRb pocket proteins reduces histone methylation
To explore the relationship between the degradation of pRb pocket proteins and activation of gene expression, changes in histone methylation around the RASSF1A promoter in TKD-treated U2OS cells were assessed. As a control, 5-aza-CdR treatment alone and 5-aza-CdR treatment plus transfection with the pSG5-RB plasmid were also performed to detect changes in histone methylation. After triple-knockdown of the pRb pocket proteins or treatment with 5-aza-CdR, we detected 2.5-and 5-fold decrease in H3K9 di-and trimethylation around the promoter of RASFF1A, whereas H3K27 trimethylation in the promoter of RASSF1A was not changed (Fig. 6A) . Interestingly, the 5-aza-CdR-induced decrease in both H3K9 di-and trimethylation was significantly reversed by transfection with the pSG5-Rb plasmid (Fig. 6A) , indicating that pRb is critical for histone methylation at H3K9. Next, a ChIP assay was performed to evaluate the role of pRb in H3K9 methylation. Enrichment for G9A (catalyzing H3K9 monoand dimethylation) and SUV39H1 (catalyzing H3K9 diments within the CpG island shore (Ϫ1050 to Ϫ198; 28 CGs) and CpG island (Ϫ197 to ϩ55; 25 CGs) in the promoter of Figure 6B shows that pRb is required for the recruitment of SUV39H1 to H3K9 around the RASSF1A promoter. 5-Aza-CdR treatment, but not TKD, induced a decrease in G9A enrichment around the RASSF1A promoter. Moreover, enrichment of histone demethylases around the RASSF1A promoter was detected by real-time ChIP PCR. As shown in Fig. 6C , 5-aza-CdR or TKD induced an increase in enrichment of KDM3B (demethylating H3K9 mono-and dimethylation), KDM4A (demethylating H3K9 di-and trimethylation), but not KDM3A (demethylating mono-and dimethylation) around the RASSF1A promoter. On the other hand, 5-aza-CdR treatment also reduced 3-fold in the enrichment of pRb in the CDKN2D promoter, which may disrupt pRb/E2F complex formation and increases gene expression (Fig. 6D) . These data clearly show that 5-aza-CdR may activate the expression of genes by changing histone methylation that is related to the loss of pRb.
DISCUSSION
The human oncoproteins gankyrin and MDM2 have been reported to mediate pRb degradation in mammalian cells (22, 23, 26) . MDM2 can directly interact with pRb, p107, and p130 and trigger ubiquitinproteasome-dependent degradation of pRb in NIH3T3, HEK293, and HCT116 cells (22) . Moreover, MDM2 facilitates an interaction between pRb and C8, a subunit of the 20S proteasome, and thereby induces ubiquitin-independent pRb degradation in C33A cells (23) . Therefore, MDM2 promotes the degradation of pRb proteins through both ubiquitin-dependent and independent proteasomal pathways, and this effect may be dependent on cell line type and/or the induction stimulus.
The interaction of MDM2 with its binding partners is regulated by post-translational modifications (24) . For example, Akt, a protein kinase, enhances MDM2-mediated ubiquitination and degradation of p53 by promoting MDM2 phosphorylation at serine 186 (27) . Another protein kinase, ataxia telangiectasia mutated (ATM), was reported to phosphorylate MDM2 at serine 395 and play a critical role in p53 activation after DNA damage (28) . Under nonstress conditions, a set of phosphorylated serine sites (S256, S260, and S262) in the acidic domain of MDM2 are reported to be phosphorylated (29) . Ionizing radiation (IR) induces dephosphorylation of serines 240, 242, 260, and 262 in the acidic domain of MDM2 (29) . The level of pRb was found to be markedly reduced after IR treatment. Presumably, this may be related to the dephosphorylation of S260 in MDM2 because the level of CK2, a serine protein kinase for this residue, decrease after IR treatment (30) . In this study, all three pocket proteins were degraded via an ubiquitin-independent proteasomal pathway in A549 cells in response to 5-aza-CdR treatment (Figs. 1A,  B and 3A-C) . Furthermore, 5-aza-CdR-induced pRb degradation may result from MDM2 dephosphorylation at S260 in the acidic domain of MDM2 (Fig. 4B) . It is interesting to note that dephosphorylation of MDM2 in its acidic domain may have different effects on different molecules. For example, dephosphorylation of MDM2 at S253 and S256 stabilizes p53 in response to IR treatment (29) , but dephosphorylation of MDM2 at S260 promotes degradation of pRb after treatment with 5-aza-CdR (Fig. 4B) . The mechanism by which dephosphorylation of MDM2 in the same acidic domain induces different effects on target proteins remains to be clarified. However, the different effects on MDM2-targeted genes when it is dephosphorylated may be dependent on specific serine sites modified by different enzymes.
5-Aza-CdR is a DNA damage inducer; its function depends on the amount of incorporation into DNA (1-3). Exposure to low-dose 5-aza-CdR for a long time may cause prolonged activation of DNA damage response pathway, which induces changes in post-translational modifications of MDM2. MDM2 activity is also controlled by a p53-MDM2 negative-feedback loop; elevated p53 protein levels lead to an increase in MDM2 expression (31) (32) (33) . Supplemental Fig. S3 shows that p53 protein level was increased in HCT116 cells treated with 5-aza-CdR for up to 96 h, which may be responsible for prolonged MDM2 activation. MDM2 activation may confer cells against 5-aza-CdR-induced DNA damage by inhibiting p53-dependent apoptosis (34, 35) .
Protein phosphatase PP2A plays a major role in the dephosphorylation of MDM2 in response to 5-aza-CdR treatment in this study. The functions of PP2A are regulated by its regulatory subunits, interacting proteins, intracellular localization (36, 37), phosphorylation, and methylation (38, 39) . Specifically, PP2A activity varies depending on its interacting proteins and the treatment conditions. As reported previously, cyclin G recruits PP2A to MDM2 and dephosphorylates MDM2 at T216 and S166, resulting in decreased binding of hypophosphorylated MDM2 to p53 (40) . PP2A has also been reported to inhibit polo-like kinase 1 and thereby induce mitotic blockade in response to DNA damage (41) . Knockdown of the B56␥ protein, a subunit of PP2A, abolishes Thr55 dephosphorylation in response to DNA damage and thereby reduces p53 stabilization (42) . In response to oxidative stress, PP2A dephosphorylates pRb at T365, T821, and T862 and thereby significantly attenuates DNA synthesis (30) . Because 5-aza-CdR is a DNA damage inducer (8, 10 -12) , it is logical to hypothesize that PP2A activity might be induced by 5-aza-CdR treatment. In fact, 5-aza-CdR was shown to specifically enhance the interaction between PP2A and MDM2, which is required for MDM2 dephosphorylation and pRb degradation (Fig. 4E-G) . Therefore, PP2A can regulate different phosphorylation sites of MDM2 and degrade related proteins under different specific conditions. pRb pocket proteins have been shown to be closely associated with gene expression by interaction with E2F (14) . In addition to the influence of the phosphorylation status of pRb on gene expression, a significant change in the level of pRb also influences gene expression. For example, knockdown of pRb pocket proteins results in an increase of p16 expression in WI38 cells (43) . pRb is also required for transcriptional repression of CDKN2D regulated by pRb/E2F complex (44) . Moreover, decrease in binding of the EZH2 enzyme and other components of the PRC complex were observed at the promoter of CDKN2A (43) . There is also a relationship between the pRb and the histone 4 lysine 20 (H4K20)-trimethylating enzymes Suv4 -20h1 and Suv4 -20h2 (45) . Consistent with previous reports, we observed that levels of H3K9 di-and trimethylation, as well as of the H3K9 methyltransferase SUV39H1 (but not G9A) were significantly decreased at the RASSF1A promoter in U2OS cells treated with 5-aza-CdR and in cells with TKD of the pocket proteins (Fig. 6A, B) . Overexpression of pRb was able to partially reverse the 5-aza-CdR-induced decreases in H3K9 trimethylation and SUV39H1 enrichment at the RASSF1A promoter, suggesting that degradation of the pocket proteins contributes to the reduction in histone methylation induced by 5-aza-CdR. However, we noticed that H3K9 dimethylation remains unchanged after overexpression of pRb, implying that 5-aza-CdR also may mediate G9A degradation (13) . In the CDKN2D promoter, enrichment of pRb decreases in U2OS cells treated with 5-aza-CdR or TKD, which may impair function of pRb/E2F repressor complex (Fig. 6D) .
Although DNA methylation is an important mechanism in transcriptional suppression (46) , recent studies indicate that changes in histone modifications can activate hypermethylated gene expression without loss of DNA methylation. For example, inhibition of the histone deacetylase SIRT1 reactivates silenced genes by promoting the acetylation of H4K16 and H3K9 independent of DNA demethylation (47). 5-Aza-CdR has been proven to decrease H3K9 dimethylation in the absence of significant DNA demethylation in the DSC3 and MASPIN promoters of breast tumor cell lines (13) . The inactivation of RASSF1A is related to histone deacetylation, H3K9 trimethylation, and the reduced binding of Sp1, which precede de novo DNA methylation (48) . Consistent with these studies, 5-aza-CdR induced the degradation of pRb pocket proteins, and the resultant decrease in histone methylation did not significantly affect the DNA methylation status at the RASSF1A promoter in this study (Fig. 5D-E) . Therefore, 5-aza-CdR may activate the expression of silenced genes via multiple mechanisms, including induction of DNA demethylation, pRb degradation, G9A degradation, and/or DNMT1 degradation.
In summary, our results suggest a novel mechanism by which 5-aza-CdR activates gene expression through the degradation of pRb. Our study may provide new insight into how gene expression is epigenetically reg-ulated, and it identified a new potential drug target for reactivating silenced tumor suppressor genes. This study is supported by National Natural Science Foundation of China grants 90919030, 31070691, 31071117, 30921062; 111 Project from the Ministry of Education of China; and grants from the Ministry of Science and Technology of China.
